Target lesion response predicts survival of patients with hepatocellular carcinoma retreated with transarterial chemoembolization
Yong‐Fa Zhang(Sun Yat-sen University), Ming Shi(Yanshan University), Rong Guo(Sun Yat-sen University), Yong Le(Sun Yat-sen University), Wei Wei(Zhujiang Hospital), Jingxian Shen(Sun Yat-sen University), Jing Zhao(Sun Yat-sen University), Guosheng Tan(Sun Yat-sen University), Hanyue Ouyang(Boston Children's Hospital)
Cited by 1
Related Papers
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
|JAMA Oncology|2019|559
Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
|Journal of Clinical Oncology|2020|217
Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy <i>versus</i> lenvatinib alone for advanced hepatocellular carcinoma
|Therapeutic Advances in Medical Oncology|2021|216
A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome
|European Journal of Endocrinology|2011|160